Abstract
The 37 kDa/67 kDa laminin receptor (LRP/LR) represents a key player for cell adhesion, is associated with the metastatic potential of solid tumors and is required for maintenance of cell viability by preventing apoptosis. LRP/LR acts as a receptor for viruses such as Sindbis virus, Venezuelean Equine Encephalitis (VEE) virus, Adeno-associated-viruses (AAV) and Dengue Virus, the latter causing 50 to 100 million infections in humans per year. LRP/LR acts further as a receptor for prions and represents a multifunctional protein subcellularly located to the nucleus, the cytoplasm and the cell surface. The receptor represents an alternative target for therapy of viral infections, cancer and prion disorders and might play additional roles in further neurodegenerative diseases such as Alzheimers disease. The species barrier in prion disorders might be at least in part determined by the presence of LRP/LR in enterocytes of the intestinal epithelium. Anti- LRP/LR antibodies, siRNAs directed against LRP mRNA, polysulfated glycanes such as pentosan polysulfate and heparan mimetics and LRP decoy mutants are promising tools for blocking or downregulating the receptor and may represent alternative therapeutics for the treatment of prion disorders, Alzheimers Disease and metastatic cancer.
Keywords: 37kDa/67kDa laminin receptor LRP/LR, prion, protein, PrP, neurodegenerative disease, HSPG, pentosan polysulfate, antibody, siRNA, species barrier
Infectious Disorders - Drug Targets
Title: LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Volume: 9 Issue: 1
Author(s): Karen Vana, Chantal Zuber, Heike Pflanz, Dominika Kolodziejczak, Georgeta Zemora, Ann-Katrin Bergmann and Stefan Weiss
Affiliation:
Keywords: 37kDa/67kDa laminin receptor LRP/LR, prion, protein, PrP, neurodegenerative disease, HSPG, pentosan polysulfate, antibody, siRNA, species barrier
Abstract: The 37 kDa/67 kDa laminin receptor (LRP/LR) represents a key player for cell adhesion, is associated with the metastatic potential of solid tumors and is required for maintenance of cell viability by preventing apoptosis. LRP/LR acts as a receptor for viruses such as Sindbis virus, Venezuelean Equine Encephalitis (VEE) virus, Adeno-associated-viruses (AAV) and Dengue Virus, the latter causing 50 to 100 million infections in humans per year. LRP/LR acts further as a receptor for prions and represents a multifunctional protein subcellularly located to the nucleus, the cytoplasm and the cell surface. The receptor represents an alternative target for therapy of viral infections, cancer and prion disorders and might play additional roles in further neurodegenerative diseases such as Alzheimers disease. The species barrier in prion disorders might be at least in part determined by the presence of LRP/LR in enterocytes of the intestinal epithelium. Anti- LRP/LR antibodies, siRNAs directed against LRP mRNA, polysulfated glycanes such as pentosan polysulfate and heparan mimetics and LRP decoy mutants are promising tools for blocking or downregulating the receptor and may represent alternative therapeutics for the treatment of prion disorders, Alzheimers Disease and metastatic cancer.
Export Options
About this article
Cite this article as:
Vana Karen, Zuber Chantal, Pflanz Heike, Kolodziejczak Dominika, Zemora Georgeta, Bergmann Ann-Katrin and Weiss Stefan, LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer, Infectious Disorders - Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/1871526510909010069
DOI https://dx.doi.org/10.2174/1871526510909010069 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adult Neurogenesis in Mesial Temporal Lobe Epilepsy: A Review of Recent Animal and Human Studies
Current Pharmaceutical Biotechnology Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Antidepressants and Sleep: Neurophysiology and Clinical Correlates
Current Psychiatry Reviews Commentary: (Research Highlights Inflammation, Demyelination and Neurodegeneration: Risky Buddies in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Novel Strategies to Improve DNA Vaccine Immunogenicity
Current Gene Therapy Editorial (Thematic Issue: Overview of Immunotherapy in Alzheimer’s Disease (AD) and Mechanisms of IVIG Neuroprotection in Preclinical Models of AD)
Current Alzheimer Research Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets T2/FLAIR Hyperintensity in Mesial Temporal Lobe: Challenging Differential Diagnosis
Current Medical Imaging Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Programmed Symptoms: Disparate Effects United by Purpose
Current Rheumatology Reviews Using Biologic Agents in Pediatric Rheumatologic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry